Patents Examined by Michael G. Hartley
  • Patent number: 10149644
    Abstract: The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid ? aggregates, these probes undergo a range of changes, qualifying them as “smart” probes. The inventors have demonstrated that probes of the invention have the capacity to monitor the progression of Alzheimer's disease in an in vivo animal model. In addition, the present invention encompasses probes useful as PET imaging agents, MRI imaging agents and multimodal imaging agents, as well as related methods of detecting and imaging amyloid ? aggregates and plaques.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: December 11, 2018
    Assignee: The General Hospital Corporation
    Inventors: Chongzhao Ran, Anna Moore
  • Patent number: 10143762
    Abstract: Provided is an articular cartilage imaging composition which can clearly distinguishably visualize a normal site and an abnormal site, i.e., a degenerative site, in articular cartilage. The articular cartilage imaging composition contains a positively charged molecule, which is labeled with a labeling molecule.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: December 4, 2018
    Assignee: Mercury Assel Management Co., Ltd.
    Inventors: Shuichi Mizuno, Nobuaki Kawaguchi, Akihiro Tsuchiya, Yoshinobu Manome
  • Patent number: 10137208
    Abstract: Nanostructures, methods of preparing nanostructures, methods of detecting targets in subjects, and methods of treating diseases in subjects, are disclosed. An embodiment, among others, of the nanostructure includes a metallic gold surface-enhanced Raman scattering nanoparticle, a Raman reporter and a protection structure. The protection structure may include a thiol-polyethylene glycol to which may be attached a target-specific probe.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: November 27, 2018
    Assignee: Emory University
    Inventors: Ximei Qian, Dominic Ansari, Shuming Nie
  • Patent number: 10137212
    Abstract: Disclosed is a compound of formula (I) or (II) in which R1-R4, R1?-R5?, Z1+-Z4, and Z1?-Z4? are as described herein. Also disclosed are a 89Zr- or 90Nb-containing complex of a compound of formula (I) or (II) and a method for obtaining a diagnostic image, such as a positron emission tomography (PET) image.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 27, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin W. Brechbiel, Francois Guerard, Yong-Sok Lee
  • Patent number: 10137209
    Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: November 27, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
  • Patent number: 10137211
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: November 27, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
  • Patent number: 10130722
    Abstract: A compound for radio metal complexation includes a chelator and one or more biological targeting vectors TV conjugated to said chelator, wherein the chelator has structure (A) or (B) or (C), based on 1,4-diazepine with groups R1, R2, R3, R4, X1, X2, X3. The compound is particularly suited for complexation of radio-isotopic metals, such as 66Ga(III), 67Ga(III) and 68Ga(III).
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: November 20, 2018
    Assignee: Johannes Gutenberg-Universität Mainz
    Inventors: Frank Rösch, Bradley Peter Waldron, David Parker
  • Patent number: 10130591
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 20, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Johannes Bartholomäus, Heinrich Kugelmann, Elisabeth Arkenau-Marić
  • Patent number: 10130725
    Abstract: A method for labeling exosomes with a radioactive substance using an amine group on surfaces of the exosomes includes providing a cell-derived exosome, treating a surface of the exosome with N-hydroxysuccinimide-azadibenzocyclooctyne (NHS-ADIBO), and mixing the treated exosome with N3-introduced chelator-radioactive substance to conduct a reaction between the chelator and an amine group present on the surface of the exosome, wherein the radioactive substance is introduced inside the exosome by the above reaction. The exosomes can be stably labeled at high labeling efficiency, and the exosomes can be favorably used as an agent for nuclear medicine imaging and therapeutic imaging for confirming the biological distribution of exosomes and whether the exosomes move to target organs and target diseases in animals including a human being.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 20, 2018
    Assignees: SNU R&DB FOUNDATION, POSTECH ACADEMY—INDUSTRY FOUNDATION
    Inventors: Dong Soo Lee, Do Won Hwang, Hongyoon Choi, Yun-Sang Lee, Jae Min Jeong, Yong Song Gho, Su Chul Jang
  • Patent number: 10124074
    Abstract: Indirect chromoendoscopy is performed by providing a subject with an orally administered composition which includes indigo carmine dye mixed with polyethylene glycol (PEG). Preferably, the subject ingests at least 160 mg of indigo carmine prior to the endoscopic procedure. This is accomplished by ingesting 1 ml to 6 L of a premixed or reconstituted indigo carmine and PEG composition up to twenty four hours prior to the endoscopic procedure.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: November 13, 2018
    Inventor: Toufic Kachaamy
  • Patent number: 10124068
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 13, 2018
    Assignee: Baxter International, Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10124111
    Abstract: Disclosed is a small molecule dye for use in imaging in the near-infrared window, namely between 1000 nm-1700 nm wavelength. The present dyes are also useful for photoacoustic imaging and photothermal therapy. The dyes have a structure of a D-A-D (donor-acceptor-donor) fluorescent compound core and side chains rendering the compounds water soluble and easily conjugated to hydrophilic polymers and/or targeting ligands. Further disclosed is compound, CH1055 that can be PEGylated, conjugated to a targeting ligand, or conjugated to taurine. Key steps utilized to assemble the core structure of the target included a cross-Suzuki coupling reaction, iron reduction and N-thionylaniline induced ring closure. Four carboxylic acid groups were introduced into the donor-acceptor-donor (D-A-D) type fluorescent compound to impart a certain aqueous solubility and to allow facile conjugation to targeting ligands.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 13, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhen Cheng, Xuechuan Hong, Hongjie Dai, Hao Chen, Alexander Antaris, Kai Cheng
  • Patent number: 10123759
    Abstract: Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 13, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David S. Bradford, Jeffrey C. Lotz
  • Patent number: 10125106
    Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: David S. Casebier, Ajay Purohit, Heike S. Radeke
  • Patent number: 10124079
    Abstract: The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: November 13, 2018
    Assignee: Blue Earth Diagnostics Limited
    Inventors: Matthew Miller, David Gauden, David Schuster, Stefano Fanti, Cristina Nanni, Lucia Zanoni, Frode Willoch, Trond Velde Bogsrud, Tore Bach-Gansmo, Alessandra Musto
  • Patent number: 10124076
    Abstract: Compositions and methods useful in connection with magnetic resonance imaging are provided. Metabolites hyperpolarized by dynanic nuclear polarization are used as reporter molecules in nuclear magnetic resonance (“NMR”) spectroscopy to study metabolic pathways and diagnose disease states. The reporter molecules include hyperpolarized glutamine and hyperpolarized acetate. The invention includes the reporter molecules, compositions including the reporter molecules in pharmaceutically acceptable carriers, methods for studying metabolic pathways that include introducing one or more of the reporter molecules to a mammalian subject and imaging a target substance using NMR spectroscopy, and kits useful in studying metabolic pathways that incorporate one or more of the reporter molecules and instructions for their use.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 13, 2018
    Assignee: HUNTINGTON MEDICAL RESEARCH INSTITUTES
    Inventors: Brian D. Ross, Pratip Bhattacharya
  • Patent number: 10124072
    Abstract: The disclosure features methods that include: administering to a subject a composition that includes particles, where each one of the particles features at least one targeting group that binds to a structural entity in the subject and at least one reacting group that reacts chemically with a reactive oxygen species in the subject, and where the particle emits luminescence when the reaction occurs; detecting the luminescence emission from the particles; and displaying an image of the subject showing locations of at least some reactive oxygen species in the subject based on the detected luminescence.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 13, 2018
    Inventors: Sunetra Ray, Daniel Ansaldi, Rajendra Singh
  • Patent number: 10117954
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 6, 2018
    Assignee: The General Hospital Corporation
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 10111970
    Abstract: Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 30, 2018
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Patent number: 10111961
    Abstract: Microparticles and nanoparticles of hydrophobized proteins and an alpha-cyclodextrin, obtained by auto-association in an aqueous medium, the hydrophobized protein being obtained by grafting of alkyl chains coming from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulation of active substances of interest, in particular in the pharmaceutical field, and the vectorization thereof for therapeutic purposes.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 30, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI
    Inventor: Kawthar Bouchemal